Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bio-Techne Corp (NASDAQ:TECH)

108.34
Delayed Data
As of Sep 23
 -1.17 / -1.07%
Today’s Change
79.95
Today|||52-Week Range
117.42
+20.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.0B

Company Description

Bio-Techne Corp. engages in the development, manufacture, and sale of biotechnology products and clinical diagnostic controls. It operates through three segments include: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment is a suppliers of specialized proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. The Clinical Controls segment develops and manufactures controls and calibrators for instruments in the global clinical market. The Protein Platforms segment develops, manufactures and sells tools to make protein analysis simpler, more quantitative and reproduceable. The company was founded on July 17, 1981 and is headquartered in Minneapolis, MN.

Contact Information

Bio-Techne Corp.
614 McKinley Place NE
Minneapolis Minnesota 55413-2610
P:(612) 379-2956
Investor Relations:

Employees

Shareholders

Mutual fund holders56.00%
Other institutional45.11%
Individual stakeholders0.57%

Top Executives

Charles R. KummethPresident, Chief Executive Officer & Director
James T. HippelCFO, VP-Finance & Chief Accounting Officer
J. Fernando BazanChief Technology Officer
Brenda S. FurlowSecretary, Senior Vice President & General Counsel
Norman David EansorSenior Vice President